This tiny “smart car” is a lot more powerful than you might think. Photo by Jon Burke/UH

The University of Houston is now leading a national consortium focused on cybersecurity in the transportation sector.

Known as the Transportation Cybersecurity Center for Advanced Research and Education, or CYBER-CARE, it's backed by a $2 million grant from U.S. Department of Transportation for its first year, with anticipated total federal funding of $10 million over five years, as part of the department's University Transportation Centers program that aims to address a number of topics in the field.

UH's center aims to "establish a fundamental knowledge base and explore advanced theories of how to best mitigate impacts of potential large-scale cyberattacks on transportation infrastructure," according to a release from the university. This includes protecting vehicle control systems, developing industry-wide best practices, responding to potential cyber incidents and introducing ways to recover quickly from cyber incidents in traffic networks.

CYBER-CARE is led by Yunpeng “Jack” Zhang, associate professor in the Department of Information Science Technology at the UH and director of the center.

"Our goal to make our intelligent transportation system (ITS) safer for all road users. That aligns well with the USDOT’s strategic goal of improving safety,” Zhang explained in a statement. “We also will promote interdisciplinary research and education across the transportation and cybersecurity domains.”

The center opened earlier this year within UH's Cullen College of Engineering’s Division of Technology. Houston and Texas colleges Rice University and Texas A&M University-Corpus Christi have joined the consortium with UH, along with Embry-Riddle Aeronautical University, University of Cincinnati and University of Hawai‘i at Mānoa.

The DOT's University Transportation Centers first launched in 1988 to conduct research. Support has ebbed and flowed over the years, but has seen some uptick recently. The Biden Administration's 2021 Bipartisan Infrastructure Law authorized 35 UTCs to receive a total of $90 million in funding from 2022 to 2026 to address issues like traffic congestion, safety, infrastructure durability and cybersecurity risks.

According to the DOT's website there are other Texas UTCs at University of Texas at Austin, University of Texas Arlington, Texas A&M University College Station, Prairie View A&M University and Texas State University.

Last year, Texas A&M also launched a new institute for research and education regarding cybersecurity. The Global Cyber Research Institute was funded by $10 million in gifts from former Texas A&M student Ray Rothrock, a venture capitalist and cybersecurity expert, and other donors.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”